Mylan

929 articles with Mylan

• Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories - June 14, 2019

  6/14/2019

  First and only once-daily, nebulized bronchodilator has potential to address unmet needs of China's nearly 100 million chronic obstructive pulmonary disease (COPD) patients   [14-June-2019]   DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , June 14, 2019 /PRNewswire/ -- Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ: TBPH) (

• Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories

  6/14/2019

  First and only once-daily, nebulized bronchodilator has potential to address unmet needs of China's nearly 100 million chronic obstructive pulmonary disease (COPD) patients   [14-June-2019]   DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , June 14, 2019 /PRNewswire/ -- Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ: TBPH) (

• Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference - May 20, 2019

  5/20/2019

  Theravance Biopharma, Inc. and Mylan N.V. announced the presentation of data from its pivotal Phase 3 efficacy studies and a 52-week safety study at the 2019 American Thoracic Society International Conference in Dallas, Texas.

• Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference

  5/20/2019

  Theravance Biopharma, Inc. and Mylan N.V. announced the presentation of data from its pivotal Phase 3 efficacy studies and a 52-week safety study at the 2019 American Thoracic Society International Conference in Dallas, Texas.

• Mylan Presents Equivalence and Device Usability Data on Wixela™ Inhub™ Compared to Advair Diskus® at American Thoracic Society International Conference

  5/18/2019

  Global pharmaceutical company Mylan N.V. announced four scientific abstracts from the Wixela™ Inhub™ development program that will be presented at the 2019 American Thoracic Society International Conference in Dallas, May 17 – May 22.

• Mylan and Biocon to Present Final Overall Survival Data for Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin®, at the American Society of Clinical Oncology (ASCO) Annual Meeting

  5/15/2019

  Ogivri™ is the first biosimilar for Herceptin® approved by the U.S. Food and Drug Administration (FDA) for all indications including HER2-positive breast and gastric cancers   [15-May-2019]   HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India , May 15, 2019 /PRNewswire/ --  Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced

• 

  Sandoz, Teva Vow to Fight Price-Fixing Allegations

  5/13/2019

  The two generic drugmakers, along with many others, have been accused of conspiring to inflate the price of more than 100 generic drugs.

• Mylan Reports First Quarter 2019 Results and Reaffirms 2019 Guidance

  5/7/2019

  Mylan N.V. announced its financial results for the three months ended March 31, 2019.

• Mylan to Release First Quarter 2019 Financial Results on May 7, 2019

  4/26/2019

  Global pharmaceutical company Mylan N.V. announced that it will release its first quarter 2019 financial results on Tues., May 7, before the open of the U.S. financial markets.

• TB Alliance and Mylan Announce Global Collaboration to Commercialize Investigational Drug Pretomanid as Part of Two Regimens to Treat Tuberculosis (TB)

  4/18/2019

  Non-profit drug developer, TB Alliance, and pharmaceutical company, Mylan N.V. (NASDAQ: MYL), today announced a global collaboration to make the experimental drug pretomanid accessible for use in two investigational drug regimens for pulmonary tuberculosis (TB).

• 

  Grocer's Union Sues AbbVie Over Humira Patents

  3/21/2019

  The United Food and Commercial Workers Local 1500 (UFCW Local 1500) filed a class action lawsuit against AbbVie for allegedly using a group of patents to maintain a monopoly on its blockbuster Humira (adalimumab).

• SBP, Mylan Present Keys to Hurricane Maria Survivor in Welcome Home Party -- Courtesy of $1M Pledge from the Mylan Charitable Foundation

  3/7/2019

  Money to Aid Ongoing Recovery Efforts in Puerto Rico, Funding the Rebuild and Repair of at Least 100 Homes

• Mylan to Present at Raymond James 40th Annual Institutional Investors Conference

  2/28/2019

  Global pharmaceutical company Mylan N.V. announced that CFO Ken Parks will present at the Raymond James 40th Annual Institutional Investors Conference in Orlando, Fla., on Tuesday, March 5, 2019, at 7:30 a.m. ET.

• Mylan Reports Fourth Quarter and Full Year 2018 Results and Provides 2019 Guidance

  2/26/2019

  Mylan N.V. announced its financial results for the fourth quarter and the year ended December 31, 2018 and provided 2019 guidance.

• Mylan Launches Generic Suboxone® Sublingual Film to Treat Opioid Dependence

  2/22/2019

  Global pharmaceutical company Mylan N.V. announced the U.S. launch of Buprenorphine and Naloxone Sublingual Film, 8 mg/2 mg and 12 mg/3 mg, a generic version of Indivior's Suboxone® Sublingual Film.

• Mylan Launches Wixela™ Inhub™ (fluticasone propionate and salmeterol inhalation powder, USP), the First Generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder), at a List Price 70% Less than the Brand

  2/12/2019

  Unique Pricing of Wixela Inhub Immediately Benefits Patients and Reduces Overall Cost to the U.S. Healthcare System

• Mylan to Release 2018 Fourth Quarter and Full Year Results and 2019 Guidance on Feb. 26, 2019

  2/11/2019

  Global pharmaceutical company Mylan N.V. announced that it will release its fourth quarter and full year 2018 financial results, as well as its 2019 financial guidance, on Tuesday, Feb. 26, after the close of the U.S. financial markets.

• 

  A Deeper Look at Drug Shortages in the U.S.

  2/1/2019

  Recently, in the U.S., there has been a shortage of an anti-anxiety drug, buspirone. The American Society of Health-System Pharmacists (ASHP) lists shortages, and as of Jan. 31, 2019, noted shortages of buspirone tablets manufactured by Accord Healthcare, Mylan and Teva Pharmaceutical.

• Mylan Announces FDA Approval of Wixela™ Inhub™ (fluticasone propionate and salmeterol inhalation powder, USP), First Generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder)

  1/31/2019

  Wixela™ Inhub™ is the first FDA-approved therapeutically equivalent generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder) for certain patients with asthma or chronic obstructive pulmonary disease (COPD)

• 

  Mylan Snags FDA Approval for Its Generic Version of GSK’s Advair

  1/31/2019

  Shares of GlaxoSmithKline took a slight dip Wednesday afternoon after the U.S. Food and Drug Administration approved Mylan NV’s generic version of Advair Diskus, a staple blockbuster drug in the U.K. pharmaceutical company’s pipeline.